M
50.14
1.00 (2.04%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Merus N.V. | Bearish | Bullish |
Stockmoo Score
-0.9
|
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 93.00 (Citigroup, 85.48%) | Buy |
| Median | 84.00 (67.53%) | |
| Low | 67.00 (Canaccord Genuity, 33.63%) | Buy |
| Average | 82.00 (63.54%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 56.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 25 Jul 2024 | 67.00 (33.63%) | Buy | 54.32 |
| Needham | 28 Jun 2024 | 92.00 (83.49%) | Buy | 59.17 |
| Citigroup | 26 Jun 2024 | 93.00 (85.48%) | Buy | 56.99 |
| B of A Securities | 25 Jun 2024 | 76.00 (51.58%) | Buy | 56.78 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |